Literature DB >> 6301651

Chronic thyrotropin releasing hormone (TRH) administration on TRH receptors and muscarinic cholinergic receptors in CNS.

N Ogawa, S Mizuno, I Nukina, S Tsukamoto, A Mori.   

Abstract

Intraperitoneal injections of thyrotropin releasing hormone (TRH, 6 mg/kg/day) to rats for 14 days resulted in a significant loss (20 25%) of TRH binding sites in the hippocampus, hypothalamus and cerebral cerebral cortex. The TRH-mediated loss was reversible and reflected a decrease in binding sites but no change in affinity. On the other hand, this TRH treatment did not affect the specific brain binding of [3H]QNB. The results suggest that TRH participates in regulating CNS-TRH receptors.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6301651     DOI： 10.1016/0006-8993(83)90328-1

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  15 in total

Review 1.  Prenatal treatment with thyrotrophin releasing hormone to prevent neonatal respiratory distress.

Authors:  F de Zegher; B Spitz; H Devlieger
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

2.  Comparative efficacy and safety of intravenous and oral administration of a TRH analogue (RX77368) in motor neuron disease.

Authors:  H Modarres-Sadeghi; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

3.  Chronic administration of Oren-gedoku-to (TJ15) inhibits ischemia-induced changes in brain indoleamine metabolism and muscarinic receptor binding in the Mongolian gerbil.

Authors:  H Kabuto; M Asanuma; S Nishibayashi; M Iida; N Ogawa
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

4.  Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat.

Authors:  G W Bennett; A R Green; C Lighton; C A Marsden
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

5.  Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.

Authors:  H Modarres-Sadeghi; H Rogers; J Emami; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

6.  Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease.

Authors:  R J Guiloff; D J Eckland; C Demaine; R C Hoare; K D MacRae; S L Lightman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

7.  Developmental and regional alteration of kappa-opioid receptors in seizure-susceptible EL mouse brain.

Authors:  T Kai; H Onishi; S Koide; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

8.  Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia.

Authors:  K Tanaka; N Ogawa; K Mizukawa; M Asanuma; Y Kondo; S Nishibayashi; A Mori
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

9.  Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia.

Authors:  Y Kondo; M Asanuma; E Iwata; F Kondo; I Miyazaki; N Ogawa
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

10.  Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis.

Authors:  M G Giovannini; F Casamenti; A Nistri; F Paoli; G Pepeu
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.